Collaboration will bring diagnostics expertise to a global, multi-stakeholder effort focused on policy, advocacy, and practical implementation
(GLOBE NEWSWIRE) — OraSure Technologies, Inc., a global leader in point-of-care and home diagnostic tests and sample management solutions, announced today that it has joined the World Coalition on Sickle Cell Disease, an international public-private partnership working to strengthen the global response to sickle cell disease.
The Coalition brings together stakeholders from across patient advocacy, government, healthcare, research, international institutions, civil society, and the private sector. Its work seeks to elevate sickle cell disease on the global health agenda, strengthen care for people living with the condition, and help countries translate policy commitments into improved services and outcomes.
As a member of the Coalition, OraSure Technologies, Inc. will provide a diagnostics manufacturer perspective, drawing on its experience in decentralized and point-of-care testing to help inform discussions around early diagnosis, screening, testing pathways, linkage to care, and health-system readiness.
“The value of earlier diagnosis is ultimately measured by what happens next,” said John Bannister, Senior Director of International Sales for OraSure. “People need clear pathways to appropriate care, supported by trained healthcare workers, effective referral systems, sustainable funding, and access to ongoing treatment. We are proud to join the World Coalition on Sickle Cell Disease and work alongside people living with sickle cell disease and the broader community to help strengthen the connections between diagnosis and care.”
“We’re excited to welcome OraSure Technologies as the newest member of the Coalition,” said Mario Ottiglio, Secretariat Lead for the World Coalition on Sickle Cell Disease. “Their diagnostics expertise will be a valuable addition to our collective efforts, helping advance timely and appropriate diagnosis that connects people to treatment, care, and long-term support.”
The collaboration will seek to keep the needs and experiences of people living with sickle cell disease at the center of the discussion. It will also consider how diagnostic strategies can be implemented across different health-system contexts, particularly where laboratory infrastructure, trained personnel, funding or access to specialist care may be limited.
